Aurinia Announced Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS in The Lancet; Study Showed Statistically Superior Complete Renal Response Rates at 52 Weeks Compared to Treatment With Mmf and Low-dose Corticosteroids Alone